Creotech Instruments (CRI) Q4 2025 earnings summary

Executive summary

• Achieved first annual net profit since public listing, driven by strong growth in space segment and successful execution of major contracts (Mikroglob, CAMILA).

• Completed the legal and operational split of the quantum systems segment, now reported as discontinued operations.

• Significant increase in revenues, EBITDA, and net income year-over-year, with robust cash flow and liquidity.

Financial highlights

• Revenue from continuing operations: 143.9m PLN, up 128.1m PLN year-over-year.

• EBITDA from continuing operations: 38.1m PLN (2024: -15.8m PLN); EBIT: 24.9m PLN (2024: -22.4m PLN).

• Net profit: 13.6m PLN (2024: -20.5m PLN); net profit from continuing operations: 19.9m PLN.

• Operating cash flow: 49.7m PLN; net cash flow: 93.9m PLN.

• Total assets: 332.7m PLN; equity: 159.0m PLN.

Outlook and guidance

• Strong order backlog from Mikroglob and CAMILA ensures revenue streams for coming years.

• Ongoing expansion of production capacity and R&D to support future growth.

• Focus on European and NATO defense markets, leveraging increased ESA funding and national defense spending.